Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Microrobot Swarm Breaks Up Bacterial Biofilms https://t.co/ZWjbJxJqos #Science #Business
    about 27 mins ago
  • After Pentagon Ends Contract, Top-Secret Scientists Group Vows To Carry On https://t.co/G5ClsQowD4 ... "We're very… https://t.co/hnp3WNu72G
    about 14 hours ago
  • Hospital, academic, and industry researchers devised automated techniques including artificial intelligence to shar… https://t.co/fxOi8PJ92w
    about 18 hours ago
  • New post on Science and Enterprise: A.I. Speeds Infant Genetic Disease Diagnostics https://t.co/Evo7kiqixY #Science #Business
    about 18 hours ago
  • A neuroscience lab created a virtual speech-generating vocal system that produces natural sounding human speech by… https://t.co/ShpRjzEWSk
    about 23 hours ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Biotech Secures $20 Million in Early Stage Financing

Bob Anderson (ImmusanT Inc.)

Bob Anderson (ImmusanT Inc.)

ImmusanT Inc. in Cambridge, Massachusetts has received $20 million in early stage financing to develop its therapy and diagnostic tools  for celiac disease. The funds from venture capital firm Vatera Healthcare Partners LLC are expected to support further research and development of the company’s Nexvax2 therapeutics and diagnostics to a proof-of-concept demonstration.

ImmusanT’s Nexvax2 therapeutic vaccine combines three peptides that elicit an immune response in patients with celiac disease who carry the immune recognition gene HLA-DQ2, which includes some 80 percent of patients. Nexvax2 is designed to help celiac disease patients alleviate the toxic effects of gluten, enabling them to return to a normal diet. ImmusanT is also developing a whole-blood functional T-cell test as a standalone diagnostic for celiac disease and a monitoring tool for the therapy.

Celiac disease is a disorder that damages the lining of the small intestine affecting the ability to absorb nutrients properly and can lead to malnutrition. The damage is due to a reaction to eating gluten, which is found in wheat, barley, rye, and possibly oats.

The company says the safety and tolerabilty of Nexvax2 have been demonstrated in a phase 1 clinical trial. Further trials are planned in 2012.

ImmusanT’s founder and Chief Scientific Officer Bob Anderson (pictured at top) discovered the three peptides responsible for making gluten toxic to people with the disease. Anderson conducted the research underlying the company’s technology while the Walter and Eliza Hall Institute in Australia, where he now leads research on the immunology of celiac disease and defining the disease-causing components of gluten.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.